Abstract Objectives of the study To describe community pharmacists' early experiences, views and attitudes with over-the-counter orlistat, 9 months post legal re-classification from November 2009 to January 2010. Setting 13,200 (81%) randomly selected registered community pharmacies across Great Britain out of a potential 16,200. Methods A cross-sectional postal questionnaire survey of the main pharmacist with greatest responsibility for over-the-counter (OTC) supply. Main outcome measures Pharmacists' early experiences, views and attitudes of orlistat supply, demographic data of respondents and personal opinions with the supply of orlistat. Results Questionnaires were returned by 32.4% (n = 4,026) of pharmacists surveyed. Just over half (51.9%, n = 2,091) reported no sales of orlistat in the previous 4 weeks with only 5.1% (n = 203) reporting frequent (5.1%) or very frequent supply in the same time frame. Two thirds (66.5%, n = 2,676) agreed or strongly agreed that the sale of orlistat was a good opportunity to extend their role as a healthcare professional and 92% (n = 3,712) felt confident in their ability to supply this product. Over half (57.9%, n = 2,334) admitted that customers frequently complained about the cost of the product and 47.8% (n = 1,926) agreed that customers could misuse the product. Conclusion Despite community pharmacists welcoming orlistat reclassification to increase medicines availability as an opportunity to extend their healthcare professional role there were concerns about poor public uptake, high cost and the potential for misuse. Exploratory studies collecting the views and experiences of the general public about the access and provision of weight management services through community pharmacies are warranted.
Introduction
Obesity and associated conditions such as type 2 diabetes, cardiovascular disease and cancer, place an enormous burden on health systems around the world [1] . With the prevalence of obesity on the increase the most recent estimates by the World Health Organisation (WHO) show that globally, more than 1 billion people are overweight or obese, accounting for up to 7% of the health care cost in most developed countries [2] . The European charter for counteracting obesity published in 2006 set a target for reversal of this trend before 2015 [3] . In 2008, the European Medicines Association (EMEA) approved the relicensing of orlistat across Europe, making it available for sale without a prescription and without the need for supervision by a general practitioner [4] . This re-classification coincided with the suspension of the marketing authorisations for sibutramine and rimonabant two centrally acting appetite suppressants, due to their unacceptable adverse effect profiles [5, 6] . This currently places orlistat as the sole pharmacological weight loss drug on the international market. At the dose licensed for sale (60 mg), orlistat blocks the absorption of *25% of ingested fat and achieves a weight loss of *5% of total body weight over a 16 week period [7] . The marketing authorisation restricts sales to individuals over 18 years of age with a BMI of C28 kg/m 2 . Good practice guidance issued by the Royal Pharmaceutical Society (formerly the RPSGB) recommends that the customers' BMI should always be measured before a sale is made and that patients should be advised to take an additional multi-vitamin supplement to counteract the loss of fat-soluble vitamins [8] . Due to its mechanism of action as a lipases inhibitor, orlistat has a considerable list of potential adverse effects patients need to be made aware of, mainly involving the gastro-intestinal (GI) system [9] . Data from long term randomised trials show that orlistat at a dose of 60 mg is both safe and effective for use in a primary care setting [10] [11] [12] but there is a paucity of published literature since the re-classification establishing its uptake and its potential impact on the wider issues of obesity.
A 3 month, open label naturalistic study carried out in 18 pharmacies across America researching compliance and behaviour changes in patients purchasing orlistat from pharmacy concluded that orlistat could be used safely and appropriately with high consumer satisfaction [13] . However, this study is limited by its open label design and the small number of pharmacies (n = 18) and patients (n = 237) included. In addition, the methodology of telephone interviews used 14, 30, 60 and 90 days after first purchase of orlistat may have influenced patients' behaviour. The re-classification of orlistat has been recognised as an opportunity for pharmacists to promote healthy lifestyle interventions such as regular exercise, diet, smoking cessation and other forms of health screening while supplying orlistat [8] . The re-classification has, however, also been heavily criticised by the medical profession as ''…an easy pill-popping solution to obesity'' which does not consider the holistic approach to adopting a healthy lifestyle [14, 15] . Since the re-classification there have been no studies exploring the pharmacist's perceptions and experiences of the value of and difficulties associated with the direct supply of orlistat.
Aim of the study
The aim of this study was to investigate the experiences, views and attitudes of community pharmacists towards the sale of orlistat across GB.
Methods
A pilot postal questionnaire was designed in accordance with published best practice applicable to surveys of health service staff and the current scientific literature [16] [17] [18] and reviewed for face and content validity by five experienced medical and pharmacy practitioners/researchers. The pilot questionnaire comprised three sections containing a mixture of 5-point Likert scale questions, semantic differential questions and open/closed questions as response options. In the first section, pharmacists' views and experiences of orlistat supply were determined, including: frequency of supply, willingness to delegate height and weight measurements to over-the-counter assistants, continuing education undertaken (CE), service ambitions of pharmacy, extension of role as health professionals, customer acceptance of supply procedures and complaints, complexity and barriers to supply, potential for patient misuse and pharmacist willingness to supply out with professional body guidelines [8] . The second section collected demographic data including: gender, age, number of years registered as pharmacist, employment status (owner, manager, relief, second, locum, non-store), type of pharmacy (large multiple (over 25 stores), medium sized multiple (5-25 stores) small multiple (2-4 stores), independent (1 store), location of pharmacy (urban, suburban, rural), possession of postgraduate qualifications and attitudes towards professional practice. The final section invited pharmacists to voice their personal opinions and experiences with the supply of orlistat. Each questionnaire included a covering letter describing the aim of the study and assurance of confidentiality. A list of all registered community pharmacy premises in GB was obtained from the RPSGB in 2009. This pilot questionnaire was mailed to 500 randomly selected community pharmacy premises throughout GB. A request was made that the questionnaire be completed by the pharmacist with greatest responsibility for over-the-counter (OTC) supply. Pilot analysis resulted in minimal changes to the wording of the questionnaire.
Results obtained from the pilot study were not included in the final data analysis. The final questionnaire was mailed to a randomly selected 13,200 (approx. 80%) registered community pharmacy premises in GB during November 2009 (excluding the pilot sample). Two reminder questionnaires were sent to all pharmacies at two-weekly intervals over a 4 week period. Data were coded and entered into SPSS for Windows version 15 (SPSS Inc.) and analysed using descriptive statistics and non-parametric chi square test to identify significant associations (P \ 0.05). Content analysis [19] was performed on the responses to the open questions relating to personal opinions and experiences with the sale of orlistat. All emerging themes and quotes, including any disagreements were discussed and finalised by the research team. Key themes are described using illustrative quotes with each respondent assigned a number.
This study was approved by the Ethical Review Panel of the School of Pharmacy and Life Sciences at Robert Gordon University Aberdeen. The North of Scotland Research Ethics Committee advised that this study did not require formal review by an NHS Ethics Committee.
Results
A total of 4,026 questionnaires were returned giving a response rate of 32.4% with 47.1% of respondents being male. Demographic data are detailed in Table 1 .
Frequency of supply
Over half of respondents (51.9%, n = 2,091) reported no sales of orlistat in the previous 4 weeks with only 5.1% (n = 172) reporting a frequent or very frequent supply in the same time frame. The majority (62.7%, n = 2,586) agreed or strongly agreed that customers asked for this product by name. Open comments highlighted a rapid decline in sales after initial interest by the general public.
''Lots of interest/sales initially but has dropped off when patients realise it is not a ''quick fix'' to weight loss'' [R-1530].
Pharmacists' attitudes towards product supply
The majority of respondents were positive that the supply of orlistat extended their role as a healthcare professional (66.4%, n = 2,676), and that it represented a valuable addition to the pharmacy range (48.7%, n = 1,966) which had the potential to generate patient satisfaction (59.5%, n = 2,398).
''Sales of orlistat allows excellent opportunities for giving additional information on lifestyle modifications and weight management services'' [R-0105]. ''I believe […] orlistat could be a useful tool in public health and has the potential to be very valuable in community'' [R-0094].
Pharmacists' confidence in product supply
Almost all pharmacists (92%, n = 3,704) felt confident in their ability to supply the product to appropriate patients. The majority of respondents (85.3%, n = 3,434) reported that they had received continuing education (CE) material related to the supply of orlistat, with drug company training resources being the source commonly cited (79.9%, n = 3,217) (see Table 2 ). However, only approximately one quarter of respondents (27%, n = 1,805) agreed that the CE materials had met their training needs. When asked if they were ''comfortable going off guidelines to supply this product'' 85.5% (n = 2,295) disagreed but admitted to delegating height and weight measurements to support staff. Delegation for these measurements was significantly associated with large multiple pharmacy chains (chi square test: P \ 0.001) but could also be associated with other variables which you have not tested for. Responses relating to the frequency of checking customers' BMI before making a supply are given in Table 3 . 
Cost as barrier to supply
When asked about the cost of supply to the patient 57.9% (n = 2,334) agreed that customers frequently complained about cost. The key issue being the cost for the duration of the treatment. Although customers where willing to receive information about orlistat and associated health issues from pharmacies, many pharmacists' reported that the customer would rather receive orlistat on prescription to reduce the cost. The location of the pharmacy had no bearing on the frequency of the cost complaint (chi square: P = 0.307).
''Too expensive. Customers are not prepared to pay that amount of money long term'' [R-2778]. ''The price and dose make the patients go to the GP to prescribe it. They ask about information but they don't buy it'' [R-3609] This reluctance to buy orlistat was in part thought to be due to misleading advertising.
''at launch most people (patients) thought this was a magic cure for overweight people. The interest has now deteriorated dramatically'' [R-0697]. ''Mis-advertising of the product in the media (TV news, newspaper etc.), saying that this is a wonder drug to make you loose weight.'' [R-3169].
Potential for misuse as barrier to supply
Almost half of respondents, (47.8%, n = 1,926) agreed that it was likely that customers could and did misuse the product.
''One customer admitted to me that she was taking it because she had a ''problem'' with food and hoped that getting diarrhoea whenever she ate chocolate would deter her'' [R-1114].
In particular concerns around the ease of access through the internet were raised.
''High risk, lots of young girls try to buy it. When they are told of the side effects or dangers they often say they will buy it on the internet as on multiple pharmacy sites it is easy to adjust weight and height to get the right BMI'' [R-745]. ''No problem in store BUT our company sold it online where people were trusted to give accurate height and weight measurements this was abused'' [R-2993].
Suggestions for change
Many suggestions for an improvement of the service were made, recognising the potential for a more sustained patient review, monitoring and documentation. 
Discussion
To our knowledge this is the first large national study to report on the experiences of community pharmacists with direct patient supply of orlistat since its re-classification in Europe. In general community pharmacists welcomed the addition of orlistat to their treatment portfolio and perceived it as an opportunity to extend their role as health professionals. Although the majority of respondent pharmacists felt confident in their ability to supply the product appropriately, educational materials were supplied predominantly by the pharmaceutical industry, which might be regarded as inappropriate and raises the possibility of bias. This issue is important and highlights the need for the delivery of appropriate independent continuing education. Despite the positive attitudes expressed by pharmacists across GB and the prevalence of weight problems, direct sales of orlistat appear to have been low. Over 50% of pharmacists reported no sale in the previous 4 weeks, citing cost as the main barrier to sale. Despite evidence that orlistat is clinically effective and safe to supply through community pharmacy [10] [11] [12] there has been a continued debate about ensuring life-style modification and the importance of intense patient follow up in conjunction with weight loss medication to achieve sustainable results [13, 20, 21] . However, pharmacy services in the UK do not cater for a sustained patient review and, although ideally placed to provide advice and medicines management as part of the multidisciplinary primary healthcare team [22] , funding for such a service was not factored into the direct patient supply of orlistat. This presents a significant gap in service provision and the continuity of care which patients prescribed orlistat through their primary or secondary care physician would otherwise receive. Our study highlighted this fact as a significant problem to pharmacists, who, although enthusiastic to provide customers with appropriate lifestyle advice, are frustrated that there is no mechanism for organising appropriate patient follow up. A recent study by Krska et al. concluded that opportunities exist for extending weight management services through community pharmacies in the UK but it was not clear on the public expectations, awareness and acceptance of these services [23] . Many other international studies have shown that there is a place for such community pharmacy led weight loss programmes. A Danish study carried out in 1999 showed sustainable weight loss results in patients taking part in ''slimming courses'' conducted by 19 community pharmacies [24] and a recent publication exploring pharmacists' opinions on the provision of such weight management services in Australian community pharmacies, identified that Pharmacists' perceived a need for such services as long as the service model was evidence based and not product focused [25] . Pharmacists reported an initial surge in sales shortly after orlistat became available but public interest has since steadily declined with almost half of all respondents reporting no sale at all in the 4 weeks prior to the study. One of the main barriers to supply emerging from the comments recorded on the questionnaire was product cost. It has been suggested that cost saving for the healthcare system is frequently the driver behind such medicines re-classification transferring cost for the state to the individual [26] . This may indeed be true for patients living in countries without a nationalised healthcare system, however, in Europe, many medicinal products are less expensive for the patient when prescribed by a medical practitioner [26] . These findings are in agreement with other studies which have assessed other recently re-classified medicines such as simvastatin where cost to the patient has also been identified as a barrier [27, 28] . ''This item is another example of a potential good POM to P switch which has been ruined by too high a cost-same as omeprazole, simvastatin, orlistat-all too costly'' [R-10078]. A second barrier to the direct supply of orlistat is the potential for patient misuse. Forty seven percent of pharmacists participating in this study agreed that it was likely that customers might abuse orlistat. To date there have been only two studies reporting orlistat misuse in patients with eating disorders [29, 30] but none since its re-classification. In particular the ease of online access for customers not eligible for purchase of orlistat over the counter alludes to the seriousness of this problem. Although the appropriateness of online sales of orlistat has not been established, a recent study looking at the accuracy of online forum answers to questions on orlistat by patients compared with clinicians found that both sources provided comparable answers. The overall quality of these answers, however, was found to be unsatisfactory with regards to accuracy and completeness [31] . The ease of online access taken together with poor accuracy of advice is a grave concern especially for a drug which has such a high adverse drug reaction and drug interaction profile [9] and which according to our findings seems to be favoured by customers with a BMI \28 kg/m 2 . This may also explain why pharmacists are not prepared to go ''off-guideline'' to supply this product despite the apparent time-consuming nature of the supply. ''Time consuming process for each supply. With limited staff resources it is stressful'' [R-9901]. Many pharmacists have admitted to delegating height and weight measurements to support staff. Although a routine BMI check before each purchase is best practice it is not a marketing authorisation requirement for the sale. This is the first national study of its kind, with a large sample size of approx. 80% of all registered pharmacy premises in GB and a response rate of 32.4% equating to almost one in four pharmacies across GB. The demographic spread of all respondents is in agreement with the latest workforce consensus of pharmacists in the UK published in 2009 covering responses from pharmacists with a wide range of experience and background [32] . Limitations of this study include the sampling process which only collected data from one pharmacist per pharmacy and the self-reported nature of the study which did not allow verification of the validity and reliability of the data. In addition, the relatively low response rate may limit the generalisability of the findings. Future studies should aim to explore the qualitative themes identified in more depth. Exploratory studies collecting the views and experiences of the general public about the access and provision of weight management services through community pharmacies are warranted.
Conclusion
Community pharmacists surveyed welcomed the addition of orlistat to the OTC range, perceiving it as a good opportunity to extend their role as health professionals. They had undertaken an array of continuing education and felt confident to supply this product. However, very few sales were made in the 9 months following re-classification with the high product cost and potential for misuse identified as areas of concern.
